REFERENCE PRICING - Making Parallel Trade in Pharmaceuticals Work
Abstract
Should governments allow parallel trade of pharmaceuticals? There is no clear-cut answer to this question, since parallel trade causes some public concerns. One is that prices might not decrease much in the home country because consumers are price insensitive as a result of medical insurance. Another one is that consumers in the foreign country might face higher prices or supply shortages, since manufacturers want to deter parallel trade. And a third one is that consuming parallel imported drug, since it is perceived as inferior, creates additional cost. This paper provides answers to these concerns by taking into account the so-called healthcare reimbursement policy of reference pricing, requiring consumers to pay the full extra cost if they don’t buy the cheaper (parallel imported) alternative. It is then shown that parallel trade gives rise to more substantial price reductions under reference pricing than under coinsurance in the home (importing) country while, contrary to intuition, leaving price unchanged in the foreign (exporting) country. Even if parallel trade creates a social cost accrued from perceived quality difference, it would not be aggravated by reference pricing.Download Info
If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.Bibliographic Info
Paper provided by University of Gothenburg, Department of Economics in its series Working Papers in Economics with number 367.Length: 35 pages
Date of creation: 17 Jun 2009
Date of revision: 05 Jan 2011
Handle: RePEc:hhs:gunwpe:0367
Contact details of provider:
Postal: Department of Economics, School of Business, Economics and Law, University of Gothenburg, Box 640, SE 405 30 GÖTEBORG, Sweden
Phone: 031-773 10 00
Web page: http://www.handels.gu.se/econ/
More information through EDIRC
Related research
Keywords: Parallel Imports; Pharmaceuticals; Reference Pricing;Find related papers by JEL classification:
- F13 - International Economics - - Trade - - - Trade Policy; International Trade Organizations
- I10 - Health, Education, and Welfare - - Health - - - General
- L12 - Industrial Organization - - Market Structure, Firm Strategy, and Market Performance - - - Monopoly; Monopolization Strategies
This paper has been announced in the following NEP Reports:
- NEP-ALL-2009-07-03 (All new papers)
References
No references listed on IDEASYou can help add them by filling out this form.
Citations
Lists
This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.Statistics
Access and download statisticsCorrections
When requesting a correction, please mention this item's handle: RePEc:hhs:gunwpe:0367For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Eva-Lena Neth).
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If references are entirely missing, you can add them using this form.
If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.
Please note that corrections may take a couple of weeks to filter through the various RePEc services.

